Market capitalization | $92.34m |
Enterprise Value | $98.08m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 4.39 |
P/S ratio (TTM) P/S ratio | 4.14 |
P/B ratio (TTM) P/B ratio | 8.36 |
Revenue growth (TTM) Revenue growth | -42.24% |
Revenue (TTM) Revenue | $22.32m |
EBIT (operating result TTM) EBIT | $-34.22m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
1 Analyst has issued a forecast CASI Pharmaceuticals Inc:
1 Analyst has issued a forecast CASI Pharmaceuticals Inc:
Dec '23 |
+/-
%
|
||
Net Profit | -27 -27 |
-
|
|
Depreciation and Amortization | 3.74 3.74 |
-
|
|
Stock Compensation | 7.22 7.22 |
-
|
|
Operating Cash Flow | -20 -20 |
-
|
|
Investments | 2.24 2.24 |
-
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -20 -20 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Wei He |
Employees | 243 |
Founded | 1991 |
Website | www.casipharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.